Stock Yards Bank & Trust Co. raised its stake in Novo Nordisk A/S (NYSE:NVO) by 0.6% during the third quarter, according to its most recent disclosure with the SEC. The firm owned 245,000 shares of the company’s stock after buying an additional 1,579 shares during the period. Novo Nordisk A/S makes up about 1.4% of Stock Yards Bank & Trust Co.’s investment portfolio, making the stock its 26th largest position. Stock Yards Bank & Trust Co.’s holdings in Novo Nordisk A/S were worth $10,189,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in NVO. Jennison Associates LLC boosted its position in Novo Nordisk A/S by 16.4% in the second quarter. Jennison Associates LLC now owns 17,400,801 shares of the company’s stock valued at $935,815,000 after buying an additional 2,452,120 shares during the last quarter. Loomis Sayles & Co. L P boosted its position in Novo Nordisk A/S by 6.3% in the second quarter. Loomis Sayles & Co. L P now owns 11,847,603 shares of the company’s stock valued at $637,164,000 after buying an additional 705,851 shares during the last quarter. WCM Investment Management CA boosted its position in Novo Nordisk A/S by 5.4% in the second quarter. WCM Investment Management CA now owns 8,779,522 shares of the company’s stock valued at $472,163,000 after buying an additional 450,232 shares during the last quarter. Fayez Sarofim & Co. boosted its position in Novo Nordisk A/S by 2.1% in the second quarter. Fayez Sarofim & Co. now owns 6,068,044 shares of the company’s stock valued at $326,612,000 after buying an additional 126,829 shares during the last quarter. Finally, Artisan Partners Limited Partnership acquired a new position in Novo Nordisk A/S during the second quarter valued at about $5,945,000. 7.34% of the stock is owned by institutional investors.

Institutional Ownership by Quarter for Novo Nordisk A/S (NYSE:NVO)

Novo Nordisk A/S (NYSE:NVO) traded up 0.37% during trading on Tuesday, hitting $32.66. The company had a trading volume of 2,717,079 shares. The company has a market capitalization of $82.52 billion, a price-to-earnings ratio of 15.58 and a beta of 0.84. The firm has a 50-day moving average of $36.32 and a 200 day moving average of $47.04. Novo Nordisk A/S has a 12-month low of $30.89 and a 12-month high of $59.00.

ILLEGAL ACTIVITY WARNING: “Novo Nordisk A/S (NVO) Stake Boosted by Stock Yards Bank & Trust Co.” was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this news story on another site, it was illegally stolen and republished in violation of United States and international trademark and copyright legislation. The correct version of this news story can be viewed at https://www.thecerbatgem.com/2016/11/29/novo-nordisk-as-nvo-stake-boosted-by-stock-yards-bank-trust-co.html.

Several research analysts have recently issued reports on NVO shares. Zacks Investment Research cut Novo Nordisk A/S from a “hold” rating to a “sell” rating in a research note on Tuesday, September 6th. JPMorgan Chase & Co. cut Novo Nordisk A/S from an “overweight” rating to a “neutral” rating in a research note on Friday, September 9th. Deutsche Bank AG raised Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research note on Monday, September 12th. Bank of America Corp. cut Novo Nordisk A/S from a “neutral” rating to an “underperform” rating in a research note on Friday, October 28th. Finally, Jefferies Group reaffirmed a “hold” rating on shares of Novo Nordisk A/S in a research note on Sunday, October 16th. Two equities research analysts have rated the stock with a sell rating, eight have given a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company’s stock. Novo Nordisk A/S presently has an average rating of “Hold” and a consensus target price of $61.33.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a healthcare company. The Company is engaged in discovery, development, manufacturing and marketing of pharmaceutical products. The Company’s business segments include diabetes and obesity care, and biopharmaceuticals. The diabetes and obesity care segment covers insulins, glucagon-like peptide-1 (GLP-1), other protein-related products (such as glucagon, protein-related delivery systems and needles), oral anti-diabetic drugs and obesity.

5 Day Chart for NYSE:NVO

Receive News & Stock Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related stocks with our FREE daily email newsletter.